Dermavant Sciences News Today

/PRNewswire/ -- DelveInsights Acne Vulgaris Market Insights report includes a comprehensive understanding of current treatment practices, acne vulgaris...

- ADORING 1 and ADORING 2 met their primary efficacy endpoints and all secondary endpoints - - ADORING 1 and ADORING 2 data were included in the sNDA filing for VTAMA cream, 1% in atopic dermatitis

In this review of dermatology news in April, we highlighted several major stories on such topics as cutaneous reactions to COVID-19, topical versus oral minoxidil, and FDA news.

A decision on approval is expected in the fourth quarter of 2024.

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Apr 29, 2024--

The announcement by Dermavant followed positive findings from the ADORING trials on tapinarof and an open label extension for children aged 2 - 17.

Approved in 2022 for psoriasis, the manufacturer has submitted an application for approval of tapinarof cream for treating atopic dermatitis in adults and children 2 years of age and older.

Visiongain has published a new report entitled Dermatological Drugs Market Report 2024-2034: Forecasts by Route of Administration (Topical, Oral,...

These new, positive data from the ADORING Phase 3 development program showed no new safety signals with long-term use as well as a significant reduction in disease burden.

/PRNewswire/ -- The Skin of Color Society (SOCS), the global leader in skin of color dermatology, reports that 2023 was a year of exceptional progress in...